论文部分内容阅读
目的 :探讨硝苯地平与卡托普利单用及联用对低氧性肺动脉高压 (PAH)的作用。方法 :30例慢性阻塞性肺疾病 (COPD)合并肺心病病人 ,通过Swan_Ganz导管分别观察了硝苯地平 2 0mg舌下含服与卡托普利 2 0mg静脉注射 ,单用或 2药联用 3组各 10例对平均肺动脉压 (MPAP)等血流动力学参数的影响。结果 :硝苯地平无明显降低MPAP、肺血管阻力 (PVR)的作用 (P >0 .0 5) ,但却显著降低体循环平均压 (MAP )、动脉血氧分压Pao2 (P <0 .0 1,P <0 .0 5)。卡托普利可显著降低MPAP和PVR(P <0 .0 5) ,对MAP和Pao2 无明显的影响。 2药联用可更显著地降低MPAP、PVR (P <0 .0 1)。结论 :卡托普利是治疗低氧性PAH的一个有效药物 ,与硝苯地平联用有协同作用
Objective: To investigate the effect of nifedipine and captopril alone and in combination on hypoxic pulmonary hypertension (PAH). Methods: 30 patients with chronic obstructive pulmonary disease (COPD) complicated with pulmonary heart disease were treated with intravenous injection of 200 mg of nifedipine and captopril 20 mg respectively by Swan-Ganz catheter. The effect of 10 patients on the hemodynamic parameters such as mean pulmonary arterial pressure (MPAP). Results: Nifedipine did not significantly reduce the effects of MPAP and pulmonary vascular resistance (PVR) (P> 0.05), but significantly reduced the mean arterial pressure (Pao2) (P <0. 0 1, P <0. 05). Captopril significantly reduced MPAP and PVR (P <0.05), but had no obvious effect on MAP and Pao2. 2 drug combination can be more significantly reduce MPAP, PVR (P <0. CONCLUSION: Captopril is an effective drug for the treatment of hypoxic PAH and has a synergistic effect with nifedipine